Lindemer, Emily R.
Salat, David H.
Smith, Eric E.
Nguyen, Khoa
Fischl, Bruce
Greve, Douglas N.
Funding for this research was provided by:
National Institutes of Health (U01 AG024904)
National Institute on Aging
National Institute of Biomedical Imaging and Bioengineering
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Araclon Biotech
BioClinica, Inc.
Biogen Idec
Bristol-Myers Squibb Company
Eisai
Elan Pharmaceuticals, Inc.
Eli Lilly and Company
EuroImmun
F. Hoffmann-La Roche Ltd
Genentech, Inc.
Fujirebio
GE Healthcare
IXICO Ltd.
Janssen Alzheimer Immunotherapy Research & Development, LLC
Johnson & Johnson Pharmaceutical Research & Development LLC.
Medpace
Merck & Co., Inc.
Meso Scale Diagnostics, LLC.
NeuroRx Research
Neurotrack Technologies
Novartis Pharmaceuticals Corporation
Pfizer
Piramal Imaging
Servier
Synarc
Takeda Pharmaceutical Company
This article is maintained by: Elsevier
Article Title: White matter signal abnormality quality differentiates mild cognitive impairment that converts to Alzheimer's disease from nonconverters
Journal Title: Neurobiology of Aging
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.neurobiolaging.2015.05.011
Content Type: article
Copyright: Copyright © 2015 Elsevier Inc. Published by Elsevier Inc. All rights reserved.